Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?

Growth & Outlook - Eli Lilly's total sales are expected to expand 33% in FY24 to $45.44 billion, with FY25 sales projected to climb another 33$60.36 billion [3] - Eli Lilly's annual earnings are slated to soar 108% in FY24 to $13.14 per share, with FY25 EPS forecasted to climb another 83$24.04 [3] - Novo Nordisk's top line is projected to expand 18% in FY24 and increase another 23% in FY25 to $49.03 billion [4] - Novo Nordisk's annual earnings are projected to rise 18$3.89 per share [4] Price Performance - Eli Lilly's stock is up +25% over the last year, roughly matching the S&P 500 [6] - Novo Nordisk shares are down -21% over the last year, attributed to subpar clinical trial results for CagriSema and patent concerns [6] - Over the last three years, Novo Nordisk stock is up more than +60%, trailing Eli Lilly's gains of +200% [7] Product Comparison - Eli Lilly's Zepbound and Novo Nordisk's Wegovy are both once-weekly injectable medications for chronic weight management [10] - Zepbound has shown greater weight loss, helping patients lose an average of 20.2% of their body weight, 47% more effective than Wegovy [2] - Zepbound was approved in November 2023, while Wegovy has been cleared for usage since June 2021 [10] Market Position - Eli Lilly appears to have the advantage in the weight loss drug market, with its stock landing a Zacks Rank 3 (Hold) [12] - Novo Nordisk shares land a Zacks Rank 4 (Sell) based on a trend of declining earnings estimate revisions [9]